Abstract
Nine patients underwent allogeneic bone-marrow transplantation as treatment for chronic granulocytic leukaemia (CGL) during the accelerated phase, a point in the course of the disease when it has progressed beyond the stable chronic phase but before the onset of blast crisis. After bone-marrow transplantation, haematological and cytogenetic studies showed ablation of all evidence of leukaemia, successful engraftment, and persistence of normal haemopoiesis in all patients. In one patient severe myelofibrosis and osteosclerosis disappeared after bone-marrow transplantation. Two patients have died of complications related to graft-versus-host disease (GvHD) but with no evidence of CGL. In one patient haematological and cytogenetic evidence of recurrent disease developed after bone-marrow transplantation, and she survives in chronic phase. Six patients are free of disability, do not require transfusions, possess normal marrow chromosomes, and have persistent clinical and haematological evidence of complete remission from CGL. Intervention with allogeneic bone-marrow transplantation during the accelerated phase of CGL can eradicate the disease and can provide normal haemopoiesis with acceptably low early morbidity and mortality. The long-term efficacy of bone-marrow transplantation as treatment for CGL, and the most effective timing of the transplantation with regard to the course of disease have yet to be determined.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 625-627 |
| Number of pages | 3 |
| Journal | The Lancet |
| Volume | 320 |
| Issue number | 8299 |
| DOIs | |
| State | Published - Sep 18 1982 |
Bibliographical note
Funding Information:Summary Nine patients underwent allogeneic bone- marrow transplantation as treatment for chronic granulocytic leukaemia (CGL) during the accelerated phase, a point in the course of the disease when it has progressed beyond the stable chronic phase but before the onset of blast crisis. After bone-marrow transplantation, haematological and cytogenetic studies showed ablation of all evidence of leukaemia, successful engraftment, and persistence of normal haemopoiesis in all patients. In one patient severe myelofibrosis and osteosclerosis disappeared after bone-marrow transplantation. Two patients have died of complications related to graft-versus-host disease (GvHD) but with no evidence of CGL. In one patient haematological and cytogenetic evidence of recurrent disease developed after bone-marrow transplantation, and she survives in chronic phase. Six patients are free of disability, do not require transfusions, possess normal marrow chromosomes, and have persistent clinical and haematological evidence of complete remission from CGL. Intervention with allogeneic bone-marrow transplantation during the accelerated phase of supported by the S. G. Warburg Voluntary Trust and by a grant from Baron Thyssen-Bornemisza. Correspondence should be addressed to J. M. G., MRC Leukaemia Unit, Hammersmith Hospital, Ducane Road, London W12 OHS.
Funding Information:
We thank the many physicians and haematologisis who referred patients included in this study, and the nursing staff on Dacie Ward, especially Sisters Wood and Ward, for the daily care of the patients. D. M. McC., A. M. W., and J. M. H. were supported by the Leukaemia Research Fund. A. S. J. B.
